Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Parenteral Drugs (India)'s annualizedNet Income for the quarter that ended in Mar. 2022 was ₹952.52 Mil. Parenteral Drugs (India)'s average total tangible assets for the quarter that ended in Mar. 2022 was ₹4,842.34 Mil. Therefore, Parenteral Drugs (India)'s annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2022 was 19.67%.
The historical rank and industry rank for Parenteral Drugs (India)'s Return-on-Tangible-Asset or its related term are showing as below:
NSE:PDPL's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.17 * Ranked among companies with meaningful Return-on-Tangible-Asset only.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Parenteral Drugs (India) Return-on-Tangible-Asset Related Terms
Parenteral Drugs (India) Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Parenteral Drugs (India)'s Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:PDPL vs ZTS, CTLT, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parenteral Drugs (India) Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Parenteral Drugs (India)'s Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2022) net income data.
What does a Return-on-Tangible-Asset of 19.67% mean?
Parenteral Drugs (India) (NSE:PDPL) has a Return-on-Tangible-Asset of 19.67% as of Mar. 2022. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Return-on-Tangible-Asset too high?
Parenteral Drugs (India)'s current Return-on-Tangible-Asset is 19.67%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.17. Parenteral Drugs (India)'s value of 19.67% is 520.5% above this industry median. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Return-on-Tangible-Asset compare to ZTS and CTLT?
Parenteral Drugs (India)'s Return-on-Tangible-Asset of 19.67% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Asset is 3.17. Parenteral Drugs (India)'s value of 19.67% is 520.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parenteral Drugs (India)'s current Return-on-Tangible-Asset of 19.67% is 520.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Parenteral Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parenteral Drugs (India)'s current Return-on-Tangible-Asset is 19.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Return-on-Tangible-Asset of 19.67%. The current Return-on-Tangible-Asset is 19.67% and 520.5% above the Drug Manufacturers industry median of 3.17. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Return-on-Tangible-Asset is 19.67% as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score
Get the complete analysis for NSE:PDPL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PDPL has been successfully added to your 
